Every day, the sun rises on Wall Street, and a plethora of professional analysts wake to issue new opinions on stocks. Here at the Fool, we use our "This Just In" column to examine some of these picks-- and the track records of the firms behind them -- so individuals can make better investing decisions.
In addition to following professional banks, anyone can use Motley Fool CAPS to monitor the collective opinions of more than 135,000 members, many of whom demonstrate better investing insight than published analysts do.
Enough top-performing CAPS members have turned bullish on Exelixis
Many CAPS members like to point to Exelixis' growing pipeline of drugs and licensing deals -- including eight cancer compounds and three others that it's working with on its own. Its latest partnership with sanofi-aventis
It also struck an excellent deal last December with Bristol-Myers Squibb
Larger players see big potential in cancer drugs, as evidenced by Johnson & Johnson's
While many other small drug companies struggle in a tight market, Exelixis has now brought in more than $400 million through licensing deals since late last year, giving it a solid cushion of cash for the near future, and leading the CEO to claim the company's in the best financial shape it's ever been in.
To see what the very best CAPS analysts are saying now about Exelixis -- as well as other winning stocks they are picking -- head on over to CAPS and have a look. The community research and resources in CAPS are totally free.
More Foolishness:
